| Literature DB >> 27863568 |
Esther Mena1, Shwetha Thippsandra1, Anusha Yanamadala1, Siddaling Redy1, Puskar Pattanayak1, Rathan M Subramaniam2.
Abstract
The concept of using tumor genomic profiling information has revolutionized personalized cancer treatment. Head and neck (HN) cancer management is being influenced by recent discoveries of activating mutations in epidermal growth factor receptor and related targeted therapies with tyrosine kinase inhibitors, targeted therapies for Kristen Rat Sarcoma, and MET proto-oncogenes. Molecular imaging using PET plays an important role in assessing the biologic behavior of HN cancer with the goal of delivering individualized cancer treatment. This review summarizes recent genomic discoveries in HN cancer and their implications for functional PET imaging in assessing response to targeted therapies, and drug resistance mechanisms.Entities:
Keywords: Head and neck cancer; Molecular imaging; Targeted therapy; Tumor genetic profiling
Mesh:
Substances:
Year: 2016 PMID: 27863568 DOI: 10.1016/j.cpet.2016.08.009
Source DB: PubMed Journal: PET Clin ISSN: 1556-8598